Patients with metastatic melanoma have a poor prognosis, with a 5‐year‐survival rate below 25%.1 Recently, the development of targeted therapies with BRAF and MEKis (BRAF and MEK inhibitors) has revolutionized the management and the prognosis of BRAFV600‐mutated melanoma patients. This evidence concerns the gene BRAF and melanoma.